Table 1 Use of specific healthcare services during the 6 months after the start of Dupilumab treatment (post-intervention period), during the corresponding 6 months of the prior year (pre-intervention period) and during the 6 months preceding the start of Dupilumab (wash-out period)
From: Effectiveness and economic impact of Dupilumab in asthma: a population-based cohort study
Pre-intervention period | Post-intervention period | Absolute (%) reduction | p-value† | |
|---|---|---|---|---|
Patients with at least one asthma prescription | 157 (89.7%) | 120 (68.6%) | 37 (23.6%) | < 0.001 |
Mean number of asthma prescriptions per patient (patients with at least one Rx) | 11.3 | 5.5 | 5.7 (50.9%) | < 0.001 |
Patients with at least one systemic glucorticoid prescription | 81 (46.0%) | 29 (16.5%) | 52 (64.2%) | < 0.001 |
Mean number of glucorticoid prescriptions per patient (patients with at least one Rx) | 4.8 | 4.4 | 0.4 (8.56%) | 0.17 |
Patients with at least one hospital admissions§ for asthma exacerbations | 9 (5.1%) | 5 (2.9%) | 4.0 (44.4%) | 0.28 |
Mean number of hospital admissions§ for asthma exacerbations¥ | 1.8 | 1.8 | 0.0 (0.0%) | 0.73 |
Wash-out period | Post-intervention period | Absolute (%) reduction | p-value† | |
|---|---|---|---|---|
Patients with at least one asthma prescription | 130 (73.9%) | 120 (68.6%) | 10 (7.0%) | 0.24 |
Mean number of asthma prescriptions per patient (patients with at least one Rx) | 4.7 | 5.5 | − 0.8 (− 17.0%) | 0.12 |
Patients with at least one systemic glucorticoid prescription | 56 (31.8%) | 29 (16.5%) | 27 (48.1%) | 0.001 |
Mean number of glucorticoid prescriptions per patient (patients with at least one Rx) | 3.0 | 4.4 | − 1.4 (− 46.0%) | 0.18 |
Patients with at least one hospital admissions§ for asthma exacerbations | 14 (8.0%) | 5 (2.9%) | 9 (64.3%) | 0.04 |
Mean number of hospital admissions§ for asthma exacerbations¥ | 1.7 | 1.8 | − 0.1 (− 5.9%) | 0.92 |